AnaptysBio
ANAB
118 hedge funds and large institutions have $993M invested in AnaptysBio in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
20% more capital invested
Capital invested by funds: $831M → $993M (+$162M)
4% more funds holding
Funds holding: 114 → 118 (+4)
6% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $1.13M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.63% less ownership
Funds ownership: 115.29% → 112.66% (-2.6%)
11% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
+$10.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$9.85M |
| 3 |
Millennium Management
New York
|
+$8.32M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.06M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$13.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.18M |
| 4 |
DM
Deerfield Management
New York
|
-$8.61M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.82M |
ANAB Hedge Fund Activity: Q4 2022 in Review
118 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2022, worth a combined $993M — up 20% from $831M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ANAB positions and 9 closed out — a net gain of 6 holders — while 34 added to existing stakes and 38 trimmed.
The largest buyer was 5AM Venture Management, opening a new position worth an estimated $10.1M. The largest seller was Woodline Partners, cutting an estimated $13.1M.
- 118 institutional investors held AnaptysBio (ANAB) as of Q4 2022, up from 114 in Q3 2022.
- Funds reported $993M of AnaptysBio stock for Q4 2022, up 20% quarter-over-quarter.
- 15 funds opened new AnaptysBio positions in Q4 2022 and 9 closed out, a net change of +6 holders.
- The largest AnaptysBio buyer in Q4 2022 was 5AM Venture Management, an estimated $10.1M added.
- The largest AnaptysBio seller in Q4 2022 was Woodline Partners, an estimated $13.1M sold.
Based on aggregated 13F filings for Q4 2022.